Analyst Upgrades Boost Two Biotech Stocks: Korro Bio and Galecto
William Blair boosts Korro Bio to Outperform with favorable risk/reward, while UBS starts Galecto at Buy with a $45 target on its promising blood disorder therapy.
/ 2 items
William Blair boosts Korro Bio to Outperform with favorable risk/reward, while UBS starts Galecto at Buy with a $45 target on its promising blood disorder therapy.
Guggenheim initiates coverage on Galecto with a Buy rating and $32 target, citing strong potential for its newly acquired drug DMR-001 and solid funding through 2029.